Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 May;33(5):684–688. doi: 10.1128/aac.33.5.684

Influence of fluoroquinolones on expression and function of P fimbriae in uropathogenic Escherichia coli.

J M Kovarik 1, I M Hoepelman 1, J Verhoef 1
PMCID: PMC172514  PMID: 2568772

Abstract

P fimbriae are the major adhesins mediating attachment of pyelonephritogenic Escherichia coli to urinary tract tissues, and they therefore constitute a recognized virulence factor. In this work, the effect of fluoroquinolones on P fimbria expression and function in E. coli SS142 and C1212 was assessed. Ciprofloxacin, fleroxacin, and norfloxacin were compared with their precursor nalidixic acid and with trimethoprim in sublethal concentrations ranging from 1/32 to 1/4 of the MIC. Fimbria function was assessed in a standard hemagglutination assay and in a parallel hemagglutination inhibition assay in which the tier of antifimbrial antiserum necessary to inhibit hemagglutination by SS142 was determined. Adhesion of antibiotic-exposed bacteria to human uroma T24 cells in suspension was also measured. Fimbria production was quantitated in an inhibition enzyme-linked immunosorbent assay. Trimethoprim produced a dose-dependent decrease of three to four hemagglutination titers for both strains and a decline in the antiserum titer from 1:16 (control) to 1:128 (1/4 MIC) for E. coli SS142. Adherence exhibited similar decrements from 130 +/- 28 (control) to 16 +/- 3 (1/4 MIC) and from 83 +/- 19 (control) to 30 +/- 11 (1/4 MIC) E. coli cells per uroepithelial cell (mean +/- standard error) for SS142 and C1212, respectively (P less than 0.015). By enzyme-linked immunosorbent assay, the inhibition following exposure decreased in a dose-dependent manner from 31% (control) to 8% (1/4 MIC). By contrast, none of the quinolones produced significant changes in the parameters assessed above. At sublethal concentrations, trimethoprim decreased fimbria production. Following exposure to fluoroquinolones, however, E. coli expressed morphologically and functionally intact P fimbriae.

Full text

PDF
684

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chopra I., Linton A. The antibacterial effects of low concentrations of antibiotics. Adv Microb Physiol. 1986;28:211–259. doi: 10.1016/s0065-2911(08)60240-4. [DOI] [PubMed] [Google Scholar]
  2. Dodd D. C., Eisenstein B. I. Antigenic quantitation of type 1 fimbriae on the surface of Escherichia coli cells by an enzyme-linked immunosorbent inhibition assay. Infect Immun. 1982 Nov;38(2):764–773. doi: 10.1128/iai.38.2.764-773.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eden C. S., Eriksson B., Hanson L. A. Adhesion of Escherichia coli to human uroepithelial cells in vitro. Infect Immun. 1977 Dec;18(3):767–774. doi: 10.1128/iai.18.3.767-774.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Edén C. S., Hanson L. A., Jodal U., Lindberg U., Akerlund A. S. Variable adherence to normal human urinary-tract epithelial cells of Escherichia coli strains associated with various forms of urinary-tract infection. Lancet. 1976 Sep 4;1(7984):490–492. [PubMed] [Google Scholar]
  5. Harber M. J., Topley N., Asscher A. W. Virulence factors of urinary pathogens. Clin Sci (Lond) 1986 Jun;70(6):531–538. doi: 10.1042/cs0700531. [DOI] [PubMed] [Google Scholar]
  6. Johnson J. R., Roberts P. L., Stamm W. E. P fimbriae and other virulence factors in Escherichia coli urosepsis: association with patients' characteristics. J Infect Dis. 1987 Jul;156(1):225–229. doi: 10.1093/infdis/156.1.225. [DOI] [PubMed] [Google Scholar]
  7. Karam D., Amgar A., Bourlioux P. Inhibition de l'adhésion bactérienne de souches d'Escherichia coli uropathogènes par des urines de patients traités par la nitroxoline. Pathol Biol (Paris) 1988 May;36(5):452–455. [PubMed] [Google Scholar]
  8. Källenius G., Svenson S., Möllby R., Cedergren B., Hultberg H., Winberg J. Structure of carbohydrate part of receptor on human uroepithelial cells for pyelonephritogenic Escherichia coli. Lancet. 1981 Sep 19;2(8247):604–606. doi: 10.1016/s0140-6736(81)92743-4. [DOI] [PubMed] [Google Scholar]
  9. Linder H., Engberg I., Baltzer I. M., Jann K., Svanborg-Edén C. Induction of inflammation by Escherichia coli on the mucosal level: requirement for adherence and endotoxin. Infect Immun. 1988 May;56(5):1309–1313. doi: 10.1128/iai.56.5.1309-1313.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mett H., Kloetzlen L., Vosbeck K. Properties of pili from Escherichia coli SS142 that mediate mannose-resistant adhesion to mammalian cells. J Bacteriol. 1983 Feb;153(2):1038–1044. doi: 10.1128/jb.153.2.1038-1044.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Neu H. C. Clinical use of the quinolones. Lancet. 1987 Dec 5;2(8571):1319–1322. doi: 10.1016/s0140-6736(87)91205-0. [DOI] [PubMed] [Google Scholar]
  12. Ofek I., Beachey E. H., Eisenstein B. I., Alkan M. L., Sharon N. Suppression of bacterial adherence by subminimal inhibitory concentrations of beta-lactam and aminoglycoside antibiotics. Rev Infect Dis. 1979 Sep-Oct;1(5):832–837. doi: 10.1093/clinids/1.5.832. [DOI] [PubMed] [Google Scholar]
  13. Orskov I., Orskov F., Birch-Andersen A., Kanamori M., Svanborg-Edén C. O, K, H and fimbrial antigens in Escherichia coli serotypes associated with pyelonephritis and cystitis. Scand J Infect Dis Suppl. 1982;33:18–25. [PubMed] [Google Scholar]
  14. Pere A., Nowicki B., Saxén H., Siitonen A., Korhonen T. K. Expression of P, type-1, and type-1C fimbriae of Escherichia coli in the urine of patients with acute urinary tract infection. J Infect Dis. 1987 Oct;156(4):567–574. doi: 10.1093/infdis/156.4.567. [DOI] [PubMed] [Google Scholar]
  15. Reid G., Sobel J. D. Bacterial adherence in the pathogenesis of urinary tract infection: a review. Rev Infect Dis. 1987 May-Jun;9(3):470–487. doi: 10.1093/clinids/9.3.470. [DOI] [PubMed] [Google Scholar]
  16. Sandberg T., Stenqvist K., Svanborg-Edén C. Effects of subminimal inhibitory concentrations of ampicillin, chloramphenicol, and nitrofurantoin on the attachment of Escherichia coli to human uroepithelial cells in vitro. Rev Infect Dis. 1979 Sep-Oct;1(5):838–844. doi: 10.1093/clinids/1.5.838. [DOI] [PubMed] [Google Scholar]
  17. Schifferli D. M., Abraham S. N., Beachey E. H. Influence of trimethoprim and sulfamethoxazole on the synthesis, expression, and function of type 1 fimbriae of Escherichia coli. J Infect Dis. 1986 Sep;154(3):490–496. doi: 10.1093/infdis/154.3.490. [DOI] [PubMed] [Google Scholar]
  18. Schifferli D. M., Beachey E. H. Bacterial adhesion: modulation by antibiotics which perturb protein synthesis. Antimicrob Agents Chemother. 1988 Nov;32(11):1603–1608. doi: 10.1128/aac.32.11.1603. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schifferli D. M., Beachey E. H. Bacterial adhesion: modulation by antibiotics with primary targets other than protein synthesis. Antimicrob Agents Chemother. 1988 Nov;32(11):1609–1613. doi: 10.1128/aac.32.11.1609. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Virkola R., Westerlund B., Holthöfer H., Parkkinen J., Kekomäki M., Korhonen T. K. Binding characteristics of Escherichia coli adhesins in human urinary bladder. Infect Immun. 1988 Oct;56(10):2615–2622. doi: 10.1128/iai.56.10.2615-2622.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Vosbeck K., Handschin H., Menge E. B., Zak O. Effects of subminimal inhibitory concentrations of antibiotics on adhesiveness of Escherichia coli in vitro. Rev Infect Dis. 1979 Sep-Oct;1(5):845–851. doi: 10.1093/clinids/1.5.845. [DOI] [PubMed] [Google Scholar]
  22. Väisänen V., Lounatmaa K., Korhonen T. K. Effects of sublethal concentrations of antimicrobial agents on the hemagglutination, adhesion, and ultrastructure of pyelonephritogenic Escherichia coli strains. Antimicrob Agents Chemother. 1982 Jul;22(1):120–127. doi: 10.1128/aac.22.1.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Westenfelder M., Pelz K., Frankenschmidt A., Vahlensieck W. Klinische Prüfung der Effektivität und Verträglichkeit von Norfloxacin in der Therapie komplizierter Harnwegsinfektionen und in der Langzeitprophylaxe rezidivierender Harnwegsinfektionen. Infection. 1987 Jan-Feb;15(1):20–24. doi: 10.1007/BF01646113. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES